Eli Lilly’s Retatrutide Data Boosts Shares, Signals Strong Future in Obesity Market
## Key Takeaways – Next-generation obesity drug retatrutide showed compelling efficacy, with a 4mg dose achieving nearly 19% weight loss in clinical trials. – The data positions retatrutide to potentially expand Eli Lilly’s leadership in the rapidly growing weight-loss treatment…
